Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients
Key result
Erythropoiesis-stimulating agents in patients with chronic heart failure and anaemia significantly reduced all-cause mortality (RR 0.61; 95% CI 0.37-0.99) and heart failure hospitalizations.
Why the study?
Does treatment with erythropoiesis-stimulating agents (ESA) improve exercise tolerance and clinical outcomes in patients with chronic heart failure and anaemia?
Population
794 patients across 11 RCTs with symptomatic chronic heart failure and mild anaemia.
Comparison
Erythropoiesis-stimulating agents, with or… vs Control (placebo in 9 of 11 studies).
Design
Meta-analysis, Randomised controlled trials, 9 studies placebo-controlled, 5…
Authors
Discussion
Loading...
Member takes
Implication
Supports ESA consideration in anemic HF to reduce mortality and hospitalizations; extends prior signals but leaves long-term safety open pending larger trials.
Study Design
Type
Meta-Analysis (n=794)
Structured PICO
Does treatment with erythropoiesis-stimulating agents (ESA) improve exercise tolerance and clinical outcomes in patients with chronic heart failure and anaemia?
P
Population
794 patients across 11 RCTs with symptomatic chronic heart failure (CHF) and mild anaemia (haemoglobin more than 10g/dL).
I
Intervention
Erythropoiesis-stimulating agents (ESA), with or without iron therapy.
C
Comparator
Control (placebo in 9 of 11 studies).
O
Outcome
Exercise tolerance, haemoglobin level, New York Heart Association (NYHA) functional class, quality of life, left-ventricular ejection fraction, B-type natriuretic peptide, CHF-related hospitalisations, all-cause mortality and adverse effects.
Main Result
Effect estimate: RR 0.61 (95% CI 0.37 to 0.99)
In patients with symptomatic chronic heart failure and mild anaemia, ESA therapy appears to improve exercise tolerance, reduce symptoms, and lower the risk of mortality and heart failure hospitalizations, though larger trials are needed to confirm safety and efficacy.
Limitations
- studies were of small sample sizes
- limited duration
- Small sample sizes
- Limited duration
- Only five studies double-blinded
Cite This Study
Ngo et al. (2010) conducted a meta-analysis in Chronic heart failure with anaemia (n=794). Erythropoiesis-stimulating agents (ESA) vs. Control was evaluated on All-cause mortality (RR 0.61, 95% CI 0.37 to 0.99). Erythropoiesis-stimulating agents in patients with chronic heart failure and anaemia significantly reduced all-cause mortality (RR 0.61; 95% CI 0.37-0.99) and heart failure hospitalizations.